Acute and chronic efficacy of felodipine in congestive heart failure. 1991

P Agostoni, and E Doria, and S Riva, and A Polese
Istituto di Cardiologia, University of Milan, Italy.

In 13 patients with congestive heart failure we tested the acute hemodynamic effects of 5 vs. 10 mg felodipine tablets, in a double-blind, cross-over study. One hour after felodipine 5 mg, echocardiographic ejection fraction (%), cardiac index (thermodilution-ml/min/m2), and pulmonary wedge pressure (mm Hg) significantly changed (from 21 +/- 2 to 26 +/- 2, 2350 +/- 150 to 2790 +/- 160, 24 +/- 4 to 17 +/- 4) while they remained steady after felodipine 10 mg. The greatest stroke index increases were associated with felodipine 5 mg in 12 patients and 10 mg in 1 patient. Therefore we evaluated (open study) the long-term (2 months- 1 year) clinical and hemodynamic efficacy following the treatment with the acutely most effective dose (twice daily). After 2 months ejection fraction, cardiac index and pulmonary wedge pressure were respectively 24 +/- 2, 2550 +/- 150, and 18 +/- 4 (12 hours after the last drug administration, n = 11, P less than 0.02 from baseline). These parameters further increased one to two hours after the following administration of felodipine. Clinical improvement (reduction of 1 functional class, according to the New York Heart Association) was observed in 8/13 patients. These 8 patients participated to the one year follow-up. In 5 patients follow-up was interrupted because of acute cardiovascular events. However, before study interruption (5 patients) or ending (3 patients) clinical status did not worsen and ejection fraction remained higher than in the pretreatment period. Therefore, low dose felodipine might be used in the treatment of congestive heart failure.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015736 Felodipine A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. Agon,Felo Biochemie,Felo-Puren,Felobeta,Felocor,Felodipin 1A Pharma,Felodipin AL,Felodipin AZU,Felodipin AbZ,Felodipin Dura,Felodipin Heumann,Felodipin Stada,Felodipin Von Ct,Felodipin-Ratiopharm,Felodur,Felogamma,Fensel,Flodil,H 154-82,Modip,Munobal,Perfudal,Plendil,Renedil,Felo Puren,Felodipin Ratiopharm,H 154 82,H 15482,Heumann, Felodipin,Von Ct, Felodipin

Related Publications

P Agostoni, and E Doria, and S Riva, and A Polese
April 1989, European heart journal,
P Agostoni, and E Doria, and S Riva, and A Polese
January 1985, European journal of clinical pharmacology,
P Agostoni, and E Doria, and S Riva, and A Polese
April 1984, British heart journal,
P Agostoni, and E Doria, and S Riva, and A Polese
January 1985, Drugs,
P Agostoni, and E Doria, and S Riva, and A Polese
January 1987, Drugs,
P Agostoni, and E Doria, and S Riva, and A Polese
August 1987, Cardiovascular drugs and therapy,
P Agostoni, and E Doria, and S Riva, and A Polese
December 1989, Cardiovascular drugs and therapy,
P Agostoni, and E Doria, and S Riva, and A Polese
June 1993, The American journal of cardiology,
P Agostoni, and E Doria, and S Riva, and A Polese
January 1988, European journal of clinical pharmacology,
P Agostoni, and E Doria, and S Riva, and A Polese
July 1989, British journal of clinical pharmacology,
Copied contents to your clipboard!